Prospective exploratory study specifically investigating the diagnostic and predictive role of 11C-Choline PET/CT and DWI MRI for response assessment in patients affected by HCC and candidate to TARE. A minimum number of 20 patients will be considered for the analysis.

For the study, all patients with a histological diagnosis of HCC and eligible for TARE, i.e. with liver predominant disease who are not eligible for curative surgery, after multidisciplinary discussion will be included. In all cases, patients will undergo 11C-Choline PET/CT and DWI MRI before starting radioembolization and will be subsequently restaged 3 months after treatment completion. A minimum number of 20 patients will be considered for the analysis.

Inclusion Criteria:

• patients with a histological diagnosis of HCC and eligible for TARE, i.e. with liver predominant disease who are not eligible for curative surgery, after multidisciplinary discussion will be included;
• obtained informed consent

Exclusion Criteria:

• patients age <18 years
• pregnancy or breast-feeding;
• patients affected by other malignancies within the last 3 years;
• disseminated extrahepatic disease;
• severely abnormal excretory liver function tests or ascites suggestive of liver failure;
• hepatopulmonary shunt >20%;
• vascular variants and abnormalities as demonstrated on pre-treatment angiography, which cannot be corrected by embolisation and which lead to reflux of hepatic arterial blood to the stomach, pancreas or bowel.

All patients affected by HCC and referred to our Institution for TARE will be enrolled.